Study guide
15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia
Key Takeaways Explain This Topic AI
Autoimmune disorders disproportionately affect women (80% of all autoimmune cases), driven by estrogen-mediated enhancement of humoral immunity, prolactin stimulation, and gene dosage effects from incomplete X-chromosome inactivation.
Systemic Lupus Erythematosus (SLE; 9:1 female-to-male ratio) is diagnosed per ACR/EULAR criteria requiring a positive ANA (≥1:80) plus weighted criteria; confirmatory autoantibodies include anti-dsDNA (correlated with disease activity and lupus nephritis) and anti-Smith (anti-Sm, highly specific).
Preconception planning in SLE mandates at least 6 consecutive months of quiescent disease; maternal anti-Ro/SSA and anti-La/SSB antibodies cross the placenta and carry risks of fetal congenital complete heart block and neonatal lupus, requiring serial fetal echocardiography from 16 to 26 weeks.
Hydroxychloroquine (HCQ) must be maintained throughout pregnancy and lactation to suppress flares and reduce preeclampsia and heart block recurrence; prednisone and azathioprine are safe in pregnancy, whereas methotrexate, mycophenolate mofetil (MMF), and cyclophosphamide are strictly contraindicated teratogens.
Antiphospholipid Syndrome (APS) presents with vascular thrombosis or defined obstetric morbidities (recurrent early losses, fetal demise ≥10 weeks, severe preeclampsia/IUGR <34 weeks) and persistent antiphospholipid antibodies, managed during pregnancy with low-dose aspirin plus prophylactic low-molecular-weight heparin (LMWH).
Last updated: October 2026
Female Predisposition to Autoimmunity & Immunologic Sex Dimorphism
Approximately 80% of all individuals diagnosed with autoimmune disorders are female . In conditions such as systemic lupus erythematosus (SLE) and Sjögren syndrome, the female-to-male ratio reaches 9:1, while in Hashimoto thyroiditis it is 8:1, and in rheumatoid arthritis (RA) it is 3:1. This female vulnerability results from hormonal, genetic, and reproductive factors:
Estrogen Modulation of Humoral Immunity: Estrogen (17-beta-estradiol) promotes B-cell survival by downregulating apoptosis, enhances immunoglobulin and autoantibody synthesis, stimulates polyclonal B-cell activation, and elevates immunostimulatory prolactin. Conversely, androgens and high-dose progesterone exert immunosuppressive effects, dampening cellular immunity and downregulating pro-inflammatory cytokines.
X-Chromosome Inactivation & Gene Dosage: The X chromosome encodes a dense cluster of immune-related genes, including TLR7 (nucleic acid sensing), CD40L , FOXP3 , and IL2RG . While one X chromosome is inactivated in female somatic cells, roughly 15% to 25% of X-linked genes escape inactivation . Overexpression or gene dosage of these escaped loci lowers the activation threshold for autoreactive lymphocytes in females.
Fetal Microchimerism: Transplacental cellular trafficking allows allogeneic fetal cells to engraft in maternal tissues for decades post-pregnancy, potentially triggering graft-versus-host-like autoimmune reactions in genetically predisposed women.
Systemic Lupus Erythematosus (SLE): Diagnostic Criteria & Clinical Hallmarks
SLE is a systemic autoimmune disease characterized by polyclonal B-cell hyperreactivity, autoantibody production, and widespread immune-complex tissue deposition.
Epidemiology & ACR/EULAR Diagnostic Criteria
SLE predominantly affects women during peak reproductive years ( ages 15 to 44 ), with a female-to-male ratio of 9:1 and increased prevalence and severity in Black, Hispanic, and Asian women.
Entry Criterion: Antinuclear antibody (ANA) titer ≥1:80 on HEp-2 cells by indirect immunofluorescence (sensitivity >95%; a negative ANA makes SLE highly improbable).
Confirmatory Serologies:
Anti-Double-Stranded DNA (anti-dsDNA): Highly specific (~95%); titers fluctuate dynamically with disease activity and correlate strongly with active lupus nephritis .
Anti-Smith (anti-Sm): Highly specific (~99%), though present in only 20% to 30% of patients; does not correlate with activity.
Complement Levels: Low serum C3 and C4 indicate immune-complex consumption during flares.
Antiphospholipid Antibodies: Present in 30% to 40% of SLE patients, conferring secondary Antiphospholipid Syndrome risks.
Multisystem Clinical Manifestations
Cutaneous: Malar "butterfly" rash (erythema over the bridge of the nose and malar eminences that characteristically SPARES the nasolabial folds , differentiating it from rosacea); photosensitivity; discoid lesions (scarring plaques with follicular plugging); painless oral or nasopharyngeal ulcers; non-scarring alopecia.
Musculoskeletal: Migratory, symmetric, non-erosive polyarthritis. Unlike RA, SLE arthritis does not produce bony erosions on radiographs (Jaccoud arthropathy represents reversible tendon laxity).
Serositis: Pleuritis and pericarditis.
Lupus Nephritis: Occurs in up to 50% of patients. Manifests as proteinuria (>0.5 g/24 hours), active urinary sediment (RBC casts, cellular casts), and rising creatinine; renal biopsy is the gold standard for ISN/RPS histologic classification (Classes I to VI; Class III focal and Class IV diffuse proliferative carry the highest risk of renal failure).
Hematologic & Neuropsychiatric: Autoimmune hemolytic anemia, leukopenia (<4,000/mcL), lymphopenia (<1,000/mcL), immune thrombocytopenia (<100,000/mcL), seizures, psychosis, and cerebritis.
- Reproductive Health, Preconception Planning & Gestational Risks in SLE
- Preconception Remission Requirement
Pregnancy should be planned strictly after SLE disease activity has been quiescent for at least 6 consecutive months on pregnancy-compatible medications, with stable renal function (creatinine <1.2 mg/dL, proteinuria <0.5 g/day, and controlled blood pressure). Conceiving during active lupus triggers maternal flares in >50% and dramatically elevates fetal loss.
Maternal Gestational Complications
Lupus Flares vs. Preeclampsia:
Lupus Renal Flare: Rising anti-dsDNA titers, falling C3/C4 complement levels, active urine sediment with RBC casts, and systemic lupus features.
Preeclampsia: Normal complement levels, stable anti-dsDNA, hyperuricemia, elevated liver transaminases, and thrombocytopenia without active urinary sediment.
Preeclampsia Prophylaxis: SLE confers a 3- to 4-fold baseline increase in preeclampsia risk; all gravidas with SLE should initiate low-dose aspirin (81 to 162 mg daily) at 12 weeks gestation .
Contraception: Estrogen-containing methods are contraindicated in women with positive antiphospholipid antibodies (US MEC Category 4); progestin-only options (IUD, implant, DMPA, POPs) and copper IUD are safe.
Neonatal Lupus Erythematosus & Congenital Complete Heart Block
Neonatal lupus is caused by transplacental transmission of maternal IgG autoantibodies, specifically anti-Ro/SSA and anti-La/SSB antibodies:
Congenital Heart Block: Maternal anti-Ro/SSA antibodies cross the placenta starting at 16 weeks, binding to fetal cardiomyocytes and the atrioventricular (AV) node. This provokes complement activation, myocarditis, and permanent dystrophic calcification and fibrosis of the AV node, resulting in congenital complete (third-degree) heart block .
Surveillance: Occurs in ~2% of anti-Ro/SSA-positive mothers, rising to 18% to 20% if a prior infant was affected. Serial fetal echocardiography every 1 to 2 weeks from 16 to 26 weeks gestation is mandatory to detect PR interval prolongation or fetal bradycardia (<100 bpm).
Cutaneous Neonatal Lupus: Transient annular erythematous plaques (periorbital "raccoon eyes") and transaminitis resolve by 6 months of age as maternal IgG clears from infant circulation.
Gestational Pharmacotherapy Safety in SLE: The Hydroxychloroquine Imperative
Medication Gestational Safety Status Clinical Rationale & Teratogenicity Risks
Hydroxychloroquine (HCQ) CONTINUE THROUGHOUT PREGNANCY & LACTATION Discontinuation precipitates maternal flares . HCQ reduces gestational flares by >60%, lowers preeclampsia risk, decreases IUGR, and reduces congenital heart block recurrence by >50%. Safe; no fetal ocular or structural toxicity.
Glucocorticoids (Prednisone, Methylprednisolone) Safe for Flares (maintain lowest effective dose, <10–20 mg/day) Placental enzyme 11-beta-hydroxysteroid dehydrogenase type 2 metabolizes 90% into inactive cortisone, shielding the fetus.
Azathioprine Safe in Pregnancy (dose ≤2 mg/kg/day) Fetal liver lacks inosinic pyrophosphorylase to convert it to active metabolites; preferred steroid-sparing agent.
Methotrexate (MTX) STRICTLY CONTRAINDICATED Methotrexate embryopathy : cranial dysostosis, facial clefts, limb hypoplasia, cardiac defects, miscarriage. Discontinue ≥3 months preconception .
Mycophenolate Mofetil (MMF) STRICTLY CONTRAINDICATED Mycophenolate embryopathy in >25%: microtia/anotia, cleft lip/palate, micrognathia, congenital heart disease. Discontinue ≥6 weeks preconception .
Cyclophosphamide STRICTLY CONTRAINDICATED Severe skeletal and visceral malformations; maternal permanent ovarian failure. Strictly avoided.
Important
Never discontinue hydroxychloroquine during pregnancy in SLE . Halting HCQ before or during pregnancy dramatically escalates maternal flares, renal decompensation, preeclampsia, and preterm delivery.
Antiphospholipid Syndrome (APS) in Women & Pregnancy
Antiphospholipid Syndrome is a systemic autoimmune thrombophilia characterized by vascular thrombosis and/or adverse pregnancy outcomes with persistent antiphospholipid antibodies.
Sydney / Revised Sapporo Diagnostic Criteria
Requires at least one clinical criterion AND at least one laboratory criterion :
Clinical Criteria:
Vascular Thrombosis: ≥1 confirmed episode of arterial, venous, or microvascular thrombosis.
Obstetric Morbidity:
- ≥3 consecutive unexplained spontaneous abortions prior to 10 weeks gestation; OR
- ≥1 unexplained fetal demise of a morphologically normal fetus at or beyond 10 weeks gestation; OR
≥1 premature birth of a normal infant prior to 34 weeks gestation due to severe preeclampsia, eclampsia, or severe placental insufficiency.
Laboratory Criteria (confirmed on ≥2 occasions ≥12 weeks apart):
Lupus Anticoagulant (LA) .
Anticardiolipin Antibodies (aCL): Medium-high titer IgG or IgM (>40 GPL/MPL units, or >99th percentile).
Anti-Beta-2 Glycoprotein I Antibodies: IgG or IgM >99th percentile.
Gestational Antithrombotic Protocols
Obstetric APS (Pregnancy Morbidity without Prior Thrombosis): Initiate low-dose aspirin (81 to 162 mg daily) preconception, and add prophylactic-dose low-molecular-weight heparin (LMWH, e.g., enoxaparin 40 mg SQ daily) upon confirmation of intrauterine pregnancy. Continue through pregnancy and for 6 weeks postpartum .
Thrombotic APS (History of Prior Thrombosis): Low-dose aspirin plus therapeutic-dose LMWH (e.g., enoxaparin 1 mg/kg SQ every 12 hours) throughout gestation and postpartum.
Contraindicated Anticoagulants: Warfarin (warfarin embryopathy: nasal hypoplasia, stippled epiphyses) and DOACs (cross placenta) are strictly contraindicated in pregnancy.
- Rheumatoid Arthritis & Fibromyalgia in Women
- Rheumatoid Arthritis (RA)
Presentation: Symmetrical polyarthritis affecting the small joints of the hands and feet (MCP, PIP, MTP; characteristically SPARING the DIP joints and thoracolumbar spine ). Cardinal feature: morning joint stiffness lasting >1 hour improving with activity; synovial thickening and boggy effusions.
Serology: Rheumatoid Factor (RF; sensitivity 70%–80%) and Anti-CCP antibodies (specificity >95%–98% ); elevated ESR and CRP.
Gestational Course: Roughly 60% to 70% of women experience spontaneous improvement or remission during pregnancy , followed by a sharp postpartum flare in up to 90% within 3 to 6 months after delivery . Pregnancy-compatible DMARDs include sulfasalazine, hydroxychloroquine, and certolizumab pegol.
Fibromyalgia
Pathophysiology: Chronic, non-inflammatory widespread musculoskeletal pain syndrome driven by central sensitization (augmented central nociceptive processing producing hyperalgesia and allodynia). Female-to-male ratio is 8:1 , onset 30 to 55 years.
Clinical Hallmarks: Diffuse bilateral pain above and below the waist for ≥3 months , profound fatigue, non-restorative sleep, cognitive dysfunction ("fibro fog"), and somatic comorbidities (IBS, tension headaches). The 2016 ACR criteria use the widespread pain index and symptom severity scale instead of a tender-point count; the exam shows diffuse tenderness WITHOUT joint swelling, warmth, or synovitis . Inflammatory markers (ESR, CRP) and muscle enzymes (CK) are completely normal.
Multimodal Management: Graded low-impact aerobic exercise, cognitive behavioral therapy (CBT), sleep hygiene, and FDA-approved pharmacotherapy: SNRIs ( duloxetine 30–60 mg daily , milnacipran) or pregabalin (150–450 mg daily). Opioids and systemic corticosteroids are strictly avoided due to lack of efficacy and hyperalgesia/dependence risks.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)
Diagnosis (National Academy of Medicine, 2015): At least 6 months of substantially reduced activity with profound fatigue, post-exertional malaise , and unrefreshing sleep, plus either cognitive impairment or orthostatic intolerance. It is roughly three times more common in women.
Exclude mimics: CBC (anemia), TSH, metabolic panel, celiac serology, sleep apnea, depression, and medication effects.
Management: Activity pacing within the patient's energy envelope (CDC no longer recommends graded exercise therapy), sleep hygiene, treatment of orthostatic symptoms and pain, and supportive counseling. Fibromyalgia and ME/CFS often coexist.